Illustration of leukemia cells with gamma-catenin protein chains

Decoding Leukemia: How Gamma-Catenin Levels Impact Treatment and Prognosis

Elliot Brynn monogram
Elliot Brynn in Health & Wellness October 2026 • 3 min read.

"New research reveals that gamma-catenin could be a key player in acute myeloid leukemia, influencing everything from treatment response to disease progression."


Acute myeloid leukemia (AML) is a complex group of blood cancers characterized by the rapid growth of abnormal myeloid cells in the bone marrow. This disrupts the production of normal blood cells and can lead to severe health complications. Understanding the underlying mechanisms that drive AML is crucial for developing more effective treatments.

Recent research has focused on the role of specific proteins within leukemia cells, seeking to identify potential targets for new therapies. Among these proteins is gamma-catenin, a molecule involved in cell adhesion and signaling. Dysregulation of gamma-catenin has been implicated in various cancers, but its precise role in AML has remained unclear.

A new study published in OncoTargets and Therapy sheds light on the clinical significance of gamma-catenin in AML. Researchers investigated the expression levels of gamma-catenin in AML patients and explored its potential impact on disease progression and treatment response. The findings suggest that gamma-catenin could serve as a valuable biomarker and a potential therapeutic target for AML.

AI Search Multiple angles on this topic

Leukemia’s Continuing Impact

Leukemia is the seventh leading cause of cancer death in the United States, according to SEER’s Cancer Stat Facts. Treatment options can often control the disease and its symptoms. The CDC’s United States Cancer Statistics combine registry data from CDC’s National Program of Cancer Registries and the National Cancer Institute’s SEER program to track cancer rates, trends, research progress, and outcomes.

From Microscopy to Classification

Recognition of leukemia began in the late 19th century with the advent of the microscope. Leeuwenhoek and Swammerdam described erythrocytes, while Lieutaud first observed globuli albicantes, later identified as lymphocytes by Hewson. The history of leukemia also includes advances in early diagnosis and treatment, classification, bone marrow and stem cell transplantation, and improved prognosis.

Gamma-Catenin: A Potential Game-Changer in AML?

Illustration of leukemia cells with gamma-catenin protein chains

The study involved analyzing bone marrow samples from 71 patients with primary AML and comparing them to samples from healthy donors. The researchers used quantitative real-time polymerase chain reaction (qRT-PCR) to measure the levels of gamma-catenin mRNA in the cells.

Here's what they discovered:

  • Elevated Gamma-Catenin in AML Patients: AML patients showed significantly higher levels of gamma-catenin compared to healthy individuals.
  • Correlation with White Blood Cell Count: Patients with lower white blood cell counts (<30×109/L) had higher gamma-catenin expression.
  • Association with CEBPa Mutation: AML patients with a mutated CEBPa gene also exhibited higher gamma-catenin levels. CEBPa is a transcription factor crucial for myeloid differentiation, and its mutation is often associated with more favorable outcomes in AML.
  • Impact on Remission: Patients with lower gamma-catenin levels were more likely to achieve complete remission after treatment.
AI Search Multiple angles on this topic

Questioning Beta-Catenin’s Role

In an MLL-AF9 acute myeloid leukemia mouse model, genetic deletion of beta-catenin did not affect AML onset in primary recipients. The same deletion also did not impair the ability of leukemic stem cells to propagate AML in secondary recipients. Deleting all four Tcf/Lef transcription factors that interact with beta-catenin likewise produced no effect in those experiments.

Why Treatment Can Fail

Further investigation is needed to clarify how gamma-catenin regulates AML cell survival and invasion. Its mechanisms for enhancing the effects of chemotherapeutic drugs also remain incompletely understood. Treatment failure remains a significant concern in AML, and a 2025 international study led by the CU Cancer Center examined why a widely used AML treatment does not work for every patient.

Comparing Treatment Approaches

AML is the most common acute leukemia in adults, with a median age at diagnosis of 68 years. Outcomes for older or medically unfit patients receiving intensive chemotherapy are poor, contributing to the need for alternative strategies. Recent non-intensive therapies have transformed the standard of care for this population, while treatment success also depends on leukemia type and stage, age, overall health, and treatment response.

To further investigate the role of gamma-catenin, the researchers conducted in vitro experiments using K562 leukemia cells. They found that reducing gamma-catenin expression suppressed cell proliferation and enhanced cell migration. Additionally, these cells became more sensitive to decitabine, a common AML treatment drug. Decitabine a cytosine analog and a DNA demethylation agent. It can induce leukemia cell differentiation and apoptosis

Personalized Medicine for AML: The Future is Here?

This research provides compelling evidence that gamma-catenin plays a significant role in AML pathogenesis. By understanding the complex interplay between gamma-catenin expression, genetic mutations, and treatment response, clinicians can begin to tailor treatment strategies for individual patients, potentially improving outcomes and reducing the burden of this challenging disease.

AI Search Multiple angles on this topic

Toward Personalized Decisions

Treatment selection is becoming more individualized as leukemia care incorporates targeted agents, molecular testing, and patient-specific factors. In chronic lymphocytic leukemia, the treatment landscape has rapidly evolved from chemoimmunotherapy to highly effective targeted agents, although limited head-to-head trials and regional differences in drug availability and molecular testing remain challenges. European LeukemiaNet recommendations for chronic myeloid leukemia have similarly shifted from cytogenetic to molecular monitoring and incorporated second-generation TKIs and treatment-free remission as a therapeutic goal.

More Effective, Less Toxic Care

NCI-funded researchers are advancing leukemia research through targeted therapies and immunotherapies. These approaches have the potential to make treatment more effective and less toxic, with some clinical advances potentially translating into improved care. Recent progress has also included advances in genomics, pathophysiology, prognostication, and highly sensitive measurable residual disease assays.

Care in Real-World Context

Real-world evidence is helping researchers examine treatment intensity and prognostic model performance in older adults with AML, including findings from the French ALFA-PPP Cohort. A separate real-world study of ponatinib in chronic-phase CML confirmed observations from clinical trials regarding its activity and toxicity pattern in relapsed or refractory disease. Clinical decisions must also account for individual circumstances, as illustrated by a case involving a 76-year-old woman with AML, chronic kidney disease, coronary artery disease, and diabetes.

What gamma-catenin adds to the AML picture

The survival figures point in a different direction from another reported analysis, which found no statistically significant difference in overall or relapse-free survival between high- and low-expression groups. Together, these findings do not establish gamma-catenin expression as a consistent survival predictor.[1] [2]

How expression and survival findings compare

In a separate survival analysis, high and low expression groups did not differ significantly in overall or relapse-free survival, including among patients with intermediate-risk cytogenetics. This contrasts with the shorter median overall survival reported for the high-expression group in another analysis.[1] [2]

Other AML findings describe fusion proteins affecting gene expression and Wnt-related signaling, while broader work notes that Wnt activity can have differing effects on blood-forming cells depending on its level. This context places gamma-catenin within a complex signaling landscape rather than establishing a single pathway explanation for AML.[3] [4]

The evidence also cautions against treating catenin behavior as uniform: some cells and patient samples did not show nuclear accumulation, and potential pathway targeting faces toxicity, complexity, and biomarker challenges.[5] [6]

Sources

  1. γ-Catenin Overexpression in AML Patients May Promote Tumor Cell Survival via Activation of the Wnt/β-Catenin Axis (pmc.ncbi.nlm.nih.gov)
  2. The clinical significance of γ-catenin in acute myeloid leukemia (pmc.ncbi.nlm.nih.gov)
  3. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. (pubmed.ncbi.nlm.nih.gov)
  4. Wnt Signaling in Leukemia and Its Bone Marrow Microenvironment (pmc.ncbi.nlm.nih.gov)
  5. γ-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of β-catenin (pmc.ncbi.nlm.nih.gov)
  6. Targeting the WNT/β-Catenin Pathway in Hematological Malignancies: From Molecular Pathogenesis to Emerging Therapeutic Strategies. (pubmed.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is gamma-catenin, and why is it important in acute myeloid leukemia?

Gamma-catenin is a protein involved in cell adhesion and signaling. In the context of acute myeloid leukemia (AML), research indicates that gamma-catenin levels are elevated in AML patients compared to healthy individuals. It's significant because its expression levels appear to impact disease progression and how patients respond to treatment. High levels of gamma-catenin are associated with lower white blood cell counts and mutations in the CEBPa gene, which influences myeloid differentiation. The implications are that gamma-catenin could serve as both a biomarker for assessing a patient's condition and a potential target for developing new AML therapies.

2

Why are elevated levels of gamma-catenin significant in acute myeloid leukemia?

Elevated levels of gamma-catenin in acute myeloid leukemia (AML) are significant because they correlate with various factors influencing the disease's behavior and treatment outcomes. Higher gamma-catenin expression is observed in patients with lower white blood cell counts and those with mutated CEBPa. More importantly, lower levels of gamma-catenin are associated with a higher likelihood of achieving complete remission after treatment. This suggests that gamma-catenin levels could potentially predict how well a patient will respond to standard therapies.

3

What is the CEBPa gene, and how is it connected to gamma-catenin levels in acute myeloid leukemia?

The CEBPa gene is a transcription factor that plays a crucial role in myeloid differentiation, which is the process by which immature blood cells develop into mature blood cells. Mutations in CEBPa are often associated with more favorable outcomes in acute myeloid leukemia (AML). The connection is that AML patients with mutated CEBPa also exhibit higher gamma-catenin levels. The implication of this association is that it adds another layer of complexity to understanding how genetic mutations and protein expression interact to influence AML progression and treatment response.

4

What is decitabine, and how does gamma-catenin affect its effectiveness in treating acute myeloid leukemia?

Decitabine is a medication used in the treatment of acute myeloid leukemia (AML). It functions as a cytosine analog and a DNA demethylation agent, which means it can induce leukemia cell differentiation and apoptosis (programmed cell death). The research indicates that reducing gamma-catenin expression in leukemia cells makes those cells more sensitive to decitabine. This suggests that targeting gamma-catenin could enhance the effectiveness of existing AML treatments like decitabine.

5

What is personalized medicine in the context of acute myeloid leukemia, and how does gamma-catenin contribute to this approach?

Personalized medicine in the context of acute myeloid leukemia (AML) involves tailoring treatment strategies to individual patients based on their unique characteristics, such as genetic mutations and protein expression levels. The importance of understanding the interplay between gamma-catenin expression, genetic mutations like CEBPa, and treatment response is that it enables clinicians to make more informed decisions about which therapies are most likely to be effective for a particular patient. By targeting specific pathways or proteins, such as gamma-catenin, personalized medicine aims to improve outcomes and reduce the burden of this challenging disease, potentially leading to more effective and less toxic treatments.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.